No products in the cart.
Pre-made Omalizumab benchmark antibody ( Whole mAb, anti-IGHE/IgE therapeutic antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-ab-398
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Omalizumab biosimilar, Whole Mab: Anti-IGHE/IgE therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Omalizumab, sold under the brand name Xolair, is a medication used to treat asthma, nasal polyps, and urticaria.
| Products Name (INN Index) | Pre-Made Omalizumab biosimilar, Whole Mab: Anti-IGHE/IgE therapeutic antibody |
|---|---|
| INN Name | Omalizumab |
| Target | IGHE |
| Format | Whole mAb |
| Derivation | NA |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Approved |
| Est. Status | Active |
| 100% SI Structure | 4x7s:HL/2xa8:HL/4x7t:HL:AB/5hys:HL:AB:EF:CD/6tcm:HL/6tcn:HL/6tco:BA/6tcp:HL |
| 99% SI Structure | 5g64:IM:HL |
| 95-98% SI Structure | None |
| Year Proposed | 2000 |
| Year Recommended | 2001 |
| Companies | Dana-Farber Cancer Institute,Genentech,John Hopkins University,Novartis |
| Conditions Approved | Allergic asthma,Urticaria |
| Conditions Active | Seasonal allergic rhinitis,Nasal polyps,Mastocytosis,Asthma,Nephritis |
| Conditions Discontinued | Hypersensitivity,Peanut hypersensitivity |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | IGHE |
| Package |
Previous slide
Next slide
